Status and Quality of Guidelines for Therapeutic Drug Monitoring Based on AGREE II Instrument
ZM Yi, X Li, Z Wang, J Qin, D Jiang, P Tian… - Clinical …, 2023 - Springer
Background With the progress of therapeutic drug monitoring (TDM) technology and the
development of evidence-based medicine, many guidelines were developed and …
development of evidence-based medicine, many guidelines were developed and …
Novel method for determination of colistin sulfate in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its clinical …
X Wang, Q Sun, X Li, G Wang, B Xing, Z Li - Journal of Pharmacological …, 2024 - Elsevier
Colistin is a last-resort antibiotic used for treating infections caused by carbapenem-resistant
Gram-negative bacteria, particularly in critically patients, nevertheless its therapeutic window …
Gram-negative bacteria, particularly in critically patients, nevertheless its therapeutic window …
A pilot clinical risk model to predict polymyxin-induced nephrotoxicity: a real-world, retrospective cohort study
MH Song, BX Xiang, CY Yang, CH Lee… - Journal of …, 2024 - academic.oup.com
Objectives Polymyxin-induced nephrotoxicity (PIN) is a major safety concern and challenge
in clinical practice, which limits the clinical use of polymyxins. This study aims to investigate …
in clinical practice, which limits the clinical use of polymyxins. This study aims to investigate …
How can polymyxin B be dosed based on current pharmacokinetic knowledge?
H Chen, Z Zhang, Z Yu - European Journal of Clinical Pharmacology, 2024 - Springer
We read with great interest the review by Wang et al., which discussed the current
pharmacokinetic (PK) knowledge of polymyxin B [1]. However, the most important issue, that …
pharmacokinetic (PK) knowledge of polymyxin B [1]. However, the most important issue, that …